C. Westland

Janssen (United States) — United States

Medicine · Health Sciences

11h-index1.5kcitations28works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(19), Hepatitis B Virus Studies(18), HIV/AIDS drug development and treatment(9), Liver Disease Diagnosis and Treatment(7), Multiple Myeloma Research and Treatments(2)

Publications28 total

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection
Journal of Antimicrobial Chemotherapy·2021· 14 citedOpen Access
Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis
Journal of Hepatology·2017· 10 cited
Safety, tolerability, pharmacokinetics and antiviral activity of AL-3778, a first-in-class, HBV core assembly modulator alone and in combination with peginterferon-alpha 2A, in treatment naive HBeAg-positive chronic hepatitis B patients
2017
AL-335, a Once-Daily Pangenotypic Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity over 7 Days in Treatment-Naïve Genotype 1-4 Patients
Journal of Hepatology·2016· 5 cited
866 ALS-2200, A NOVEL ONCE-DAILY NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATED POTENT ANTIVIRAL ACTIVITY IN TREATMENT-NAÏVE PATIENTS WITH COMPENSATED CIRRHOSIS OR GENOTYPE 2–4 CHRONIC HEPATITIS C
Journal of Hepatology·2013· 4 cited
Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.
Journal of Clinical Oncology·2011· 6 cited
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.
Journal of Clinical Oncology·2010· 10 cited
Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients
Journal of Viral Hepatitis·2005· 67 cited
Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies
Kidney International·2004· 160 citedOpen Access
45 HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients
Journal of Hepatology·2004· 17 cited
382 In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation RTN236T in the HBV polymerase
Journal of Hepatology·2004· 22 cited
Financial Dynamics: A System for Valuing Technology Companies
2003· 1 cited
In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector
Antiviral Research·2003· 86 cited
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 1Gilead Sciences gratefully acknowledges the patients, investigators, and study site personnel who participated in clinical trials GS-98-437 and GS-98-438.
Gastroenterology·2003· 223 citedOpen Access
Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV)
Journal of Hepatology·2003· 41 cited
Resistance profile of adefovir dipivoxil (ADV) in immunocompetent and immunocompromised chronic hepatitis B patients after 48 weeks of adefovir dipivoxil therapy
Journal of Hepatology·2003· 8 cited
Predicting HBEAG loss by HBV DNA early kinetics and HBV genotype during treatment of HBEAG+ chronic hepatitis B (CHB) patients with adefovir dipivoxil (ADV)
Journal of Hepatology·2003· 3 cited
Comparison of viral replication fitness of wild-type and lamivudine-resistant HBV in patients
Journal of Hepatology·2003
1141 Complete genotypic and phenotypic analyses of HBV mutations identified in HBEAG-negative chronic hepatitis B patients receiving 96 weeks of adefovir dipivoxil (ADV)
Hepatology·2003· 13 cited
10 Resistance surveillance of liver transplantation patients with lamivudine-resistant hepatitis B virus (HBV) after 96 weeks of adefovir dipivoxil treatment
Hepatology·2003· 3 cited
page 1 of 2Next →

Frequent Co-authors

Carol Brosgart(14), Craig S. Gibbs(12), John Fry(8), William E. Delaney(6), Michael Wulfsohn(6), S. Xiong(6), John Fry(4), Patrick Marcellin(3), Shanshan Xiong(3), Michael D. Miller(3), Vincent Thibault(3), Y. Benhamou(3), Thomas N. Kakuda(3), Sushmita Chanda(3), L.M. Blatt(3), Leo Beigelman(3), Hamid Namini(3), Michael G. Miller(3), Stephanos J. Hadziyannis(2), Lennart Mucke(2)